KoBioLabs

KoBioLabs Rule of 40

The Rule of 40 of KoBioLabs (348150.KQ) as of Nov 16, 2026 is -12.56 %. In the previous year, Rule of 40 was 96.86 % — a change of -112.97% (lower).

Rule of 40

-12.56 %

YoY

-112.97%

Last updated:

Rule of 40 of KoBioLabs is 2025 -12.56 % . Rule of 40 of KoBioLabs was 2024 96.86 % . It decreases by -112.97% lower compared to the previous year.

The KoBioLabs Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2019
-476.69 KRW
Jan 1, 2020
427.55 KRW
Jan 1, 2021
-601.89 KRW
Jan 1, 2022
126.32 KRW
Jan 1, 2023
129.90 KRW
Jan 1, 2024
96.86 KRW
Jan 1, 2025
-12.56 KRW
The KoBioLabs Rule of 40 history
YEARRule of 40YoY
-12.56 %-112.97%
96.86 %-25.43%
129.90 %+2.83%
126.32 %-120.99%
-601.89 %-240.78%
427.55 %-189.69%
-476.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

KoBioLabs Stock analysis

What does KoBioLabs do? KoBioLabs Inc., headquartered in Seoul, South Korea, operates in the Health Care sector, specializing in biotechnology. The company focuses on research and development of the microbiome, developing products such as Bioviom and Queens henna FOODOLOGY, as well as new microbiome drugs. It provides commissioned research services and sells its products domestically and internationally. Listed on 18 November 2020, KoBioLabs is active in both domestic and overseas markets. KoBioLabs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about KoBioLabs stock

Rule of 40 of KoBioLabs is -12.56 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 KoBioLabs since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — KoBioLabs

All Key Metrics — KoBioLabs